Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy
出版年份 2019 全文链接
标题
Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy
作者
关键词
-
出版物
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-04-25
DOI
10.1093/ndt/gfz108
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents
- (2019) C Macchi et al. European Journal of Preventive Cardiology
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
- (2018) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease
- (2018) Peter P. Toth et al. KIDNEY INTERNATIONAL
- Elevated urinary monocyte chemoattractant protein-1 levels in children with Henoch-Schonlein purpura nephritis
- (2018) Jiapei Wang et al. Pediatrics and Neonatology
- Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
- (2018) Andrea Baragetti et al. PHARMACOLOGICAL RESEARCH
- What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
- (2018) Maciej Banach et al. CARDIOVASCULAR RESEARCH
- Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
- (2018) Pragyi Shrestha et al. CELLULAR SIGNALLING
- Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
- (2017) Monika Kohli et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease
- (2017) Christopher P. Larsen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
- (2017) Shipra Agrawal et al. Nature Reviews Nephrology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
- (2017) Yuki Awanami et al. BMC Nephrology
- Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment
- (2017) Yinghui Deng et al. Experimental and Therapeutic Medicine
- Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors
- (2017) Abdur Rahman Khan et al. Circulation-Cardiovascular Quality and Outcomes
- Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
- (2017) Dave L Dixon et al. Drug Design Development and Therapy
- Metabolic injury-induced NLRP3 inflammasome activation dampens phospholipid degradation
- (2017) Elena Rampanelli et al. Scientific Reports
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Angiotensin II induces cholesterol accumulation and injury in podocytes
- (2017) Yingjie Yang et al. Scientific Reports
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury
- (2016) Yang Zhang et al. International Journal of Biological Sciences
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences
- (2016) Nosratola D. Vaziri KIDNEY INTERNATIONAL
- LDL-Cholesterol Increases the Transcytosis of Molecules through Endothelial Monolayers
- (2016) Ana Magalhaes et al. PLoS One
- PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension
- (2015) Jean-Mathieu Berger et al. ATHEROSCLEROSIS
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
- (2015) Michael M Page et al. Expert Opinion on Drug Metabolism & Toxicology
- Activation of mTORC1 disrupted LDL receptor pathway: A potential new mechanism for the progression of non-alcoholic fatty liver disease
- (2015) Jing Liu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—A KDIGO consensus report
- (2015) Kai-Uwe Eckardt et al. KIDNEY INTERNATIONAL
- HDL abnormalities in nephrotic syndrome and chronic kidney disease
- (2015) Nosratola D. Vaziri Nature Reviews Nephrology
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study
- (2014) Eri Muso et al. Clinical and Experimental Nephrology
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
- (2014) E. A. Stein et al. EUROPEAN HEART JOURNAL
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Nephrotic syndrome redux
- (2014) R. J. Glassock et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular Cholesterol Transport Proteins in Diabetic Nephropathy
- (2014) Joseph G. S. Tsun et al. PLoS One
- Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
- (2013) Kyubok Jin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1
- (2013) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Interaction of RAS Activation and Lipid Disorders Accelerates the Progression of Glomerulosclerosis
- (2013) Kun-Ling Ma et al. International Journal of Medical Sciences
- The role of signalling in cellular cholesterol homeostasis
- (2013) Winnie Luu et al. IUBMB LIFE
- Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
- (2013) Tanja Kosenko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome
- (2013) S. Liu et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Mechanisms of renal NaCl retention in proteinuric disease
- (2012) P. Svenningsen et al. Acta Physiologica
- Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
- (2012) Arjan J. Kwakernaak et al. ATHEROSCLEROSIS
- Lipid Nephrotoxicity: New Concept for an Old Disease
- (2012) Leonard Gyebi et al. CURRENT HYPERTENSION REPORTS
- Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes
- (2012) Arianna Carolina Rosa et al. INFLAMMATION RESEARCH
- Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2012) Vikas Sharotri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway
- (2012) Weiming Xu et al. MOLECULES
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- LDL-Apheresis: Technical and Clinical Aspects
- (2012) Rolf Bambauer et al. TheScientificWorldJOURNAL
- Regulation of cholesterol homeostasis
- (2011) Leigh Goedeke et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Renal lipid metabolism and lipotoxicity
- (2010) Ion Alexandru Bobulescu CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein
- (2009) Paul Gutwein et al. AMERICAN JOURNAL OF PATHOLOGY
- Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes
- (2009) E. Tarabra et al. DIABETES
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An update on the lipid nephrotoxicity hypothesis
- (2009) Xiong Z. Ruan et al. Nature Reviews Nephrology
- Inflammation stimulates the expression of PCSK9
- (2008) Kenneth R. Feingold et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidemia: A preliminary report
- (2008) Osama Gheith et al. European Journal of Internal Medicine
- Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice
- (2008) Kun L. Ma et al. HEPATOLOGY
- Are Podocytes Passive or Provocative in Proteinuric Glomerular Pathology?
- (2008) P. G. Tipping JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- High Absolute Risks and Predictors of Venous and Arterial Thromboembolic Events in Patients With Nephrotic Syndrome
- (2007) Bakhtawar K. Mahmoodi et al. CIRCULATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now